Enteric Disease Testing Market Size, Trends, and Growth Analysis 2032

The Enteric Disease Testing Market was valued at USD 3,987 million in 2024 and is projected to grow steadily at a CAGR of 3.5% from 2025 to 2032. This growth trajectory highlights the market’s crucial role in combating a persistent and often overlooked global health threat—enteric diseases.
Enteric diseases are infections of the intestinal tract caused by various pathogens, including bacteria, viruses, and parasites. These infections can lead to gastrointestinal symptoms such as diarrhea, vomiting, nausea, abdominal pain, and fever. Transmission typically occurs via contaminated food or water, poor sanitation, or close contact with infected individuals. Given their rapid spread and high prevalence, particularly in developing countries, accurate and timely diagnosis is essential.
Drivers Behind Market Growth
1. Increasing Disease Burden Worldwide
According to the World Health Organization (WHO), enteric diseases remain a leading cause of morbidity and mortality, particularly in low-income regions. Conditions such as rotavirus, norovirus, salmonellosis, and cholera continue to impact millions, particularly children under five. These alarming statistics are fueling demand for effective diagnostic tools.
2. Advancements in Diagnostic Technologies
The enteric disease testing landscape has evolved dramatically with innovations in molecular diagnostics, immunoassays, and rapid testing kits. Multiplex PCR platforms now allow simultaneous detection of multiple pathogens with higher accuracy and faster turnaround times, revolutionizing the clinical diagnosis process.
3. Public Health Initiatives and Global Surveillance
Governments and global health bodies are actively promoting awareness, sanitation initiatives, and disease surveillance programs. Testing plays a central role in these efforts, not only to detect outbreaks early but also to monitor antimicrobial resistance and track epidemiological patterns.